SCHEMBL2584764

SCHEMBL2584764

COC(=O)C=Cc1cn([C@@H]2O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)c(=O)nc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
THRB P10828 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
ALDH1A1 P00352 2/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CA9 Q16790 13/20 0.41
CA1 P00915 12/20 0.41
CA2 P00918 12/20 0.41
CA12 O43570 12/20 0.41
CA14 Q9ULX7 10/20 0.41
PRKCA P17252 1/20 0.41
AKT1 P31749 1/20 0.41
PTK2 Q05397 1/20 0.41
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2580227 0.93 LMNA (0.41) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2585720 0.89 LMNA (0.50) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2585719 0.89 LMNA (0.50) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2587230 0.88 ALDH1A1 (0.47) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2587233 0.88 ALDH1A1 (0.47) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2587743 0.88 CA1 (0.40) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2579634 0.86 LMNA (0.48) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2799301 0.84 ALDH1A1 (0.41) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2580496 0.84 ALDH1A1 (0.41) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2584265 0.82 TLR7 (0.31) LMNATHRBSMN1; SMN2HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 US disclosed
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION GILEAD SCIENCES, INC. (US) 2014-02-27 US disclosed
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PHARMASSET, INC. 2011-11-03 US disclosed
EP-1411954-B1 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION PHARMASSET INC (US) 2010-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION SLC29A1, PNP, SLC29A2 LMNA 1019/4885THRB 3626/4885SMN1; SMN2 214/4885
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PNP, ALPP, XDH LMNA 694/4885THRB 4276/4885SMN1; SMN2 676/4885
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, SLC29A2, PNP LMNA 821/4885THRB 2955/4885SMN1; SMN2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.